(Source: Stemline Therapeutics Inc) NEW YORK, July 1, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk, announced today that it has been added to the Russell 3000® Index, effective prior to the market open on Monday, July 1, 2013. Annual reconstitution of Russell's U.S. indexes captures the 4,000...
↧